Potency of HDM Sublingual AIT Tablets in Assuring the Persistency of Asthma Control in HDM Allergic Patients With Severe Asthma, Treated With Tezepelumab
Potency of HDM Sublingual AIT Tablets in Assuring the Persistency of Asthma Control in HDM Allergic Patients With Severe Asthma, Treated With Tezepelumab
Not yet recruiting · NCT07013123 · Registry updated 2025-06-10Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Potency of HDM Sublingual AIT Tablets in Assuring the Persistency of Asthma Control in HDM Allergic Patients With Severe Asthma, Treated With Tezepelumab | Dust Mite Allergy, Hypersensitivity, Immediate, Respiratory Hypersensitivity, Rhinitis, Allergic, asthma, bronchial disorder, immune system disorder, lung disorder, nasal disorder, obstructive lung disease, otorhinolaryngologic disease, perennial allergic rhinitis, respiratory system disorder, rhinitis | Not yet recruiting | Phase 3 | 2025-06-10 | NCT07013123 |
5 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| ALK-Abelló A/S | 1 |
| AstraZeneca | 806 |
| ThermoFisher Scientific Brahms Biomarkers France | 2 |
| University hospital of Nîmes | 1 |
| University Hospital, Montpellier | 211 |
0 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| No products are listed yet. | |||